Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.72 |
| ▸ | TERT | O14746 | 15/20 | 0.69 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5344753 | 0.95 | P2RY12 (0.70) | P2RY12TERT | |
| SCHEMBL5338189 | 0.88 | TERT (0.69) | P2RY12TERTCASP3CASP2CASP7 | |
| SCHEMBL5332048 | 0.82 | TERT (1.00) | P2RY12TERT | |
| SCHEMBL10068096 | 0.80 | P2RY12 (0.90) | P2RY12TERTCA12CA9KDM4E | |
| SCHEMBL5337897 | 0.79 | TERT (1.00) | P2RY12TERT | |
| SCHEMBL5339895 | 0.78 | TERT (1.00) | P2RY12TERTALDH1A1 | |
| SCHEMBL31312543 | 0.78 | TERT (0.76) | P2RY12TERTKDM4EALDH1A1HPGD | |
| SCHEMBL7931748 | 0.77 | P2RY12 (0.82) | P2RY12TERTCASP6KDM4EALDH1A1 | |
| SCHEMBL11304144 | 0.77 | CASP3 (0.50) | P2RY12TERTCASP3CASP2CASP7 | |
| SCHEMBL14355586 | 0.77 | TERT (1.00) | P2RY12TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
| EP-1363888-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | Cancer Research Technology Limited (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002008193-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | TERT, ACIN1, NAT1 | P2RY12 3821/4885TERT 1/4885CASP3 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.